Maintenance immunotherapy in metastatic breast cancer

Oncology Reports

Volumn 20, Issue 5, 2008, Pages 1173-1179

  Recchia, Francesco ^a,b,d   Sica, Gigliola ^a   Candeloro, Giampiero ^a   Necozione, Stefano ^c   Bisegna, Roberta ^a   Bratta, Massimo ^b   Rea, Silvio ^b,c  

^a CATHOLIC UNIVERSITY   (Italy)

^b Fondazione 'Carlo Ferri'   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d NONE   (Italy)

Author keywords

13 Cis retinoic acid; Breast cancer; Immunotherapy; Interleukin 2

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; INTERLEUKIN 2; ISOTRETINOIN; METHOTREXATE; PACLITAXEL; PARACETAMOL; TAMOXIFEN; RETINOIC ACID;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; BEDTIME DOSAGE; BREAST CANCER; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG FEVER; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGICAL PARAMETERS; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTE; MAJOR CLINICAL STUDY; METASTASIS; NATURAL KILLER CELL; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; THYROID DISEASE; URTICARIA; WORLD HEALTH ORGANIZATION; BREAST TUMOR; CLINICAL TRIAL; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; METHODOLOGY; MIDDLE AGED; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KAPLAN-MEIERS ESTIMATE; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; LYMPHOCYTES; MIDDLE AGED; TRETINOIN;

EID: 58149359342     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000126     Document Type: Article

References (39)

1. Gennari A, Conte P, Rosso R, Orlandini C and Bruzzi P: Survival of metastatic breast carcinoma patients a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104: 1742-1750, 2005.
2. Coates AS, Stockler MR and Wilcken NRC: Controversies in metastatic breast cancer: optimal duration of chemotherapy. Am Soc Clin Oncol Educ Book 21: 119-121, 2003.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3547-3549, 2003.
4. Li X, Creighton C, Wong H, Hilsenbeck SG, Osborne CK, Rosen JM, Lewis MT, Chang JC and Duncan DL: Decrease in tumorigenic breast cancer stem cells in primary breast cancers with neoadjuvant lapatinib. Breast Cancer Res Treat 106: (suppl 1), abstract #82, 2007.
5. Mathe G and Reizenstein P: Managing minimal residual malignant disease. Oncology 43: 137-142, 1986.
6. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, Watnick RS, Straume O, Akslen LA, Folkman J and Almog N: A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 98: 316-325, 2006.
7. Mozaffari F, Lindemalm C, Choudhury A, Granstam-Björneklett H, Helander I, Lekander M, Mikaelsson E, Nilsson B, Ojutkangas ML, Osterborg A, Bergkvist L and Mellstedt H: NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. Br J Cancer 97: 105-111, 2007.
8. Finke J, Ferrone S, Frey A, Mufson A and Ochoa A: Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today 4: 158-160, 1999.
9. Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, Wexler LH, Adde MA, McClure LL and Gress RE: Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 84: 2221-2228, 1994.
10. Smith KA: Interleukin-2: inception, impact and implications. Science 240: 1169-1176, 1988.
11. Disis ML and Kim LK: Global role of the immune system in identifying cancer initiation and limiting disease progression. J Clin Oncol 23: 8923-8925, 2005.
12. Fox FE, Kubin M, Cassin M, Niu Z, Trinchieri G, Cooper KD and Rook AH: Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells. J Interferon Cytokine Res 19: 407-415, 1999.
13. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA and White DE: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474-484, 1989.
14. Recchia F, De Filippis S, Rosselli M, Saggio G, Cesta A, Fumagalli L and Rea S: Phase IB study of subcutaneously administered interleukin-2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer. Clin Cancer Res 7: 1251-1257, 2001.
15. Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G, Necozione S, Fumagalli L and Rea S: Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinoma. J Immunother 30: 448-454, 2007.
16. Recchia F, Saggio G, Nuzzo A, Biondi E, Di Blasio A, Cesta A, Candeloro G, Alesse E and Rea S: Multicenter phase II study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer. J Immunother 29: 87-94, 2006.
17. Recchia F, Saggio G, Cesta A, Candeloro G, Nuzzo A, Lombardo M, Carta G and Rea S: Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer. Int J Oncol 27: 1039-1046, 2005.
18. Recchia F, Saggio G, Cesta A, Candeloro G, Di Blasio A, Amiconi G, Lombardo M, Nuzzo A, Lalli A, Alesse E, Necozione S and Rea S: Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer. Cancer Immunol Immunother 56: 699-708, 2007.
19. Recchia F, Saggio G, Candeloro G, Cesta A, Amiconi G, Di Blasio A, Necozione S and Rea S: Chemoimmunotherapy in the treatment of metastatic gastric cancer. Anticancer Drugs 18: 597-604, 2007.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
21. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Ass 53: 457-481, 1958.
22. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU and Hortobagyi GN: Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. Cancer 85: 104-111, 1999.
23. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A and Liberati A: Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439-3460, 1998.
24. Gennari A, Amadori D, De Lena M, Nanni O, Bruzzi P, Lo Russo V, Manzione L and Conte PF: Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24: 3912-3917, 2006.
25. Alba E, Ruiz-Borrego M, Martín M, Margelí, M, Rodríguez-Lescure A, Sánchez-Rovira P, Ruiz A, Ribelles N, Calvo E and Casado A: Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 25, 18S: 1007, 2007.
26. Fidler IJ and Poste G: The cellular heterogeneity of malignant neoplasms: implication for adjuvant chemotherapy. Sem Oncol 12: 207-222, 1985.
27. Pinzon-Charry A, Ho CS, Maxwell T, McGuckin MA, Schmidt C, Furnival C, Pyke CM and López JA: Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer. Br J Cancer 97: 1251-1259, 2007.
28. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22: 531-562, 2004.
29. Polanczyk MJ, Carson BD, Subramanian S, Afentoulis M, Vandenbark AA, Ziegler SF and Offner H: Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol 173: 2227-2230, 2004.
30. Chung M, Chang HR, Bland KI and Wanebo HJ: Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 77: 97-103, 1996.
31. Sporn MB and Roberts AB: Role of retinoids in differentiation and carcinogenesis. Cancer Res 43: 3034-3040, 1983.
32. Toma S, Isnardi L, Raffo P, Dastoli G, De Francisci E, Riccardi L, Palumbo R and Bollag W: Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines: growth inhibition and apoptosis induction. Int J Cancer 70: 619-627, 1997.
33. Butler WB and Fontana JA: Responses to retinoic acid of tamoxifen-sensitive and resistant sublines of human breast cancer cell line MCF-7. Cancer Res 52: 6164-6167, 1992.
34. Patel JB, Mehta J, Belosay A, Sabnis G, Khandelwal A, Brodie AM, Soprano DR and Njar VC: Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer 96: 1204-1215, 2007.
35. Belosay A, Brodie AM and Njar VC: Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells. Cancer Res 66: 11485-11493, 2006.
36. Prabhala RH, Garenwal HS, Hicks MJ, Sampliner RE and Watson RR: The effects of 13-cis-Retinoic acid and beta-carotene on cellular immunity in humans. Cancer 67: 1556-1560, 1991.
37. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM and Chen SH: Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66: 1123-1131, 2006.
38. Hengesbach L and Hoag K: Physiological concentrations of retinoic acid favor myeloid dendritic cell development over granulocyte development in cultures of bone marrow cells from mice. J Nutr 134: 2653-2659, 2004.
39. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R and Gabrilovich D: All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 63: 4441-4449, 2003.